Pelletier Allen L, Rojas-Roldan Ledy, Coffin Janis
Medical College of Georgia at Augusta University, Augusta, GA, USA.
Am Fam Physician. 2016 Aug 1;94(3):219-26.
Vision loss affects 37 million Americans older than 50 years and one in four who are older than 80 years. The U.S. Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in adults older than 65 years. However, family physicians play a critical role in identifying persons who are at risk of vision loss, counseling patients, and referring patients for disease-specific treatment. The conditions that cause most cases of vision loss in older patients are age-related macular degeneration, glaucoma, ocular complications of diabetes mellitus, and age-related cataracts. Vitamin supplements can delay the progression of age-related macular degeneration. Intravitreal injection of a vascular endothelial growth factor inhibitor can preserve vision in the neovascular form of macular degeneration. Medicated eye drops reduce intraocular pressure and can delay the progression of vision loss in patients with glaucoma, but adherence to treatment is poor. Laser trabeculoplasty also lowers intraocular pressure and preserves vision in patients with primary open-angle glaucoma, but long-term studies are needed to identify who is most likely to benefit from surgery. Tight glycemic control in adults with diabetes slows the progression of diabetic retinopathy, but must be balanced against the risks of hypoglycemia and death in older adults. Fenofibrate also slows progression of diabetic retinopathy. Panretinal photocoagulation is the mainstay of treatment for diabetic retinopathy, whereas vascular endothelial growth factor inhibitors slow vision loss resulting from diabetic macular edema. Preoperative testing before cataract surgery does not improve outcomes and is not recommended.
视力丧失影响着3700万50岁以上的美国人,以及四分之一80岁以上的美国人。美国预防服务工作组得出结论,目前的证据不足以评估对65岁以上成年人进行视力筛查的利弊平衡。然而,家庭医生在识别有视力丧失风险的人、为患者提供咨询以及将患者转介接受特定疾病治疗方面发挥着关键作用。导致老年患者大多数视力丧失病例的疾病是年龄相关性黄斑变性、青光眼、糖尿病的眼部并发症和年龄相关性白内障。维生素补充剂可以延缓年龄相关性黄斑变性的进展。玻璃体内注射血管内皮生长因子抑制剂可以在新生血管性黄斑变性中保留视力。眼药水可以降低眼压,并能延缓青光眼患者视力丧失的进展,但治疗依从性较差。激光小梁成形术也能降低眼压,并能保留原发性开角型青光眼患者的视力,但需要长期研究来确定谁最有可能从手术中获益。糖尿病成年人严格控制血糖可减缓糖尿病视网膜病变的进展,但必须权衡老年人低血糖和死亡的风险。非诺贝特也能减缓糖尿病视网膜病变的进展。全视网膜光凝是糖尿病视网膜病变治疗的主要方法,而血管内皮生长因子抑制剂可减缓糖尿病性黄斑水肿导致的视力丧失。白内障手术前的术前检查并不能改善预后,不建议进行。